How soon will my triglycerides drop after starting Mounjaro?

The trials in the FDA label measured lipids at 72 weeks, so the published numbers reflect long-term use. Triglycerides tend to track weight loss, which builds over months as the dose rises. A repeat lipid panel a few months into the maintenance dose gives a fair picture.

Is Zepbound better than Mounjaro for cholesterol?

No. Both contain tirzepatide at the same doses, so the lipid effects are the same. The difference is the approved use: Mounjaro for type 2 diabetes and heart risk reduction, Zepbound for weight management and sleep apnea.

Can Mounjaro raise LDL cholesterol?

In the SURMOUNT-2 diabetes trial, LDL rose slightly on tirzepatide (1.8% to 4.1%), though less than on placebo (7.4%). Rapid weight loss can shift LDL in some people. Your prescriber can check this with a routine lipid panel.

Do I still need to watch my diet for cholesterol on Mounjaro?

Yes. The ADA recommends a Mediterranean or DASH eating pattern with less saturated and trans fat and more fiber for people with diabetes. Diet changes add to the drug's effect on triglycerides and help LDL, which the drug moves only a little.

Does Mounjaro help people with very high triglycerides?

The main trials enrolled people with average triglycerides near 125 to 165 mg/dL, not severe hypertriglyceridemia. Very high triglycerides raise pancreatitis risk and need their own treatment plan. Discuss this with your prescriber before starting.

Does Mounjaro Lower Cholesterol and Triglycerides?

The short answer: Yes, but mostly triglycerides. In the main obesity trial, triglycerides fell 21% to 29% on tirzepatide (the drug in Mounjaro) versus 6% on placebo. LDL cholesterol fell only about 5% to 7%, a small change next to what a statin does. HDL, the "good" cholesterol, went up about 7% to 10%.

How much does Mounjaro lower triglycerides?

Triglycerides show the largest lipid change on tirzepatide. The best published numbers sit in the FDA label for Zepbound, which is the same drug as Mounjaro, approved for weight loss. The label reports lipid results from two 72-week trials.

Adults with obesity, no diabetes (SURMOUNT-1, 2,539 people): triglycerides fell 21.2%, 23.8%, and 29.1% on the 5 mg, 10 mg, and 15 mg doses. Placebo fell 5.6%.
Adults with obesity and type 2 diabetes (SURMOUNT-2, 938 people): triglycerides fell 27.1% on 10 mg and 27.3% on 15 mg. Placebo fell 3.3%.

After subtracting the placebo effect, the extra drop was about 16% to 25%, depending on dose. People in the diabetes trial started higher, at a geometric mean near 160 mg/dL, versus about 128 mg/dL in the non-diabetes trial.

A 2024 meta-analysis of 13 randomized trials found the same pattern. Compared with controls, triglycerides fell 13.2% at 5 mg, 17.6% at 10 mg, and 22.1% at 15 mg. The effect grew with dose. The SURMOUNT-1 results themselves were published in the New England Journal of Medicine, which reported improvement in all prespecified cardiometabolic measures.

What happens to LDL and total cholesterol?

LDL moves much less than triglycerides. In SURMOUNT-1, LDL fell 4.6%, 5.6%, and 7.1% on the three doses, versus 1.7% on placebo. The placebo-adjusted drop at 5 mg was not statistically clear. At 10 mg and 15 mg it was about 4% to 6%.

In the diabetes trial, LDL actually rose in every group. It rose 7.4% on placebo, 1.8% on 10 mg, and 4.1% on 15 mg. So tirzepatide mainly blunted a rise rather than causing a clear fall.

Total cholesterol followed LDL. It fell 3.8% to 6.3% on tirzepatide in SURMOUNT-1, versus 1.8% on placebo. Non-HDL cholesterol, which captures all the particles that can clog arteries, fell a bit more: 8.0% to 11.7% versus 2.3%.

The meta-analysis put the pooled LDL drop at 5.6% to 7.8% versus controls. A 2025 systematic review focused on LDL called the reduction moderate and mostly seen at the 15 mg dose. It also found wide variation between studies and shorter follow-up than ideal.

One caveat applies to all of these lipid numbers. The FDA label notes the lipid endpoints were not controlled for type I error. That means they are supportive findings, not primary proof.

Does Mounjaro raise HDL, the "good" cholesterol?

Yes, modestly. HDL rose 6.9% to 9.2% on tirzepatide in SURMOUNT-1, while placebo fell 0.7%. In the diabetes trial, HDL rose 8.2% on 10 mg and 9.7% on 15 mg, versus 0.2% on placebo.

The meta-analysis found a pooled HDL rise of 3.8% to 6.9% over controls, again larger at higher doses. A higher HDL is a good sign, but drugs that raise HDL alone have not been proven to cut heart events. Treat it as part of the overall pattern.

Why do lipids improve on tirzepatide?

Most of the change tracks with weight loss and better insulin sensitivity. SURMOUNT-1 participants lost 15.0% to 20.9% of body weight over 72 weeks, per the NEJM report. Losing weight lowers the liver's output of triglyceride-rich particles, and higher insulin sensitivity helps clear them from the blood.

Liver fat matters too. Fatty liver is closely tied to high triglycerides, and tirzepatide reduces liver fat. Our guide to Mounjaro and fatty liver (MASH) covers that evidence. For how the dual GIP and GLP-1 action works, see how tirzepatide works.

The benefit depends on staying on the drug. In a withdrawal trial in the Zepbound label (SURMOUNT-4), people switched to placebo after 36 weeks regained weight. Their triglycerides and total cholesterol rose again over the next year, while those who stayed on treatment kept lower levels.

Does this lower heart attack and stroke risk?

The best evidence here is SURPASS-CVOT, published in the New England Journal of Medicine in December 2025. It enrolled 13,299 adults with type 2 diabetes and heart or blood vessel disease. It compared tirzepatide with dulaglutide (Trulicity), a GLP-1 drug already shown to reduce heart events.

Heart attack, stroke, or cardiovascular death occurred in 12.2% of the tirzepatide group and 13.1% of the dulaglutide group. The hazard ratio was 0.92 (95.3% CI 0.83 to 1.01). That met the test for noninferiority, but superiority over dulaglutide was not shown.

The current Mounjaro label now includes an indication to reduce the risk of major cardiovascular events in adults with type 2 diabetes at high risk. The label notes that trial investigators were told to adjust lipid, glucose, and blood pressure drugs to local standards. So the trial does not isolate the effect of lipid changes alone.

For a side-by-side look at the two most common options, see Mounjaro vs Ozempic.

Can Mounjaro replace a statin?

No. A 5% to 8% LDL drop is small, and LDL is the main target for preventing heart disease. Statins remain the first-line LDL drug in the American Diabetes Association Standards of Care 2026, Section 10.

The ADA also advises a lipid profile at diagnosis and then yearly for adults with diabetes not on a statin. For people on a statin, it advises an LDL check 4 to 12 weeks after starting or changing the dose, then yearly. Diet advice centers on a Mediterranean or DASH pattern, less saturated and trans fat, and more viscous fiber.

In practice, tirzepatide and a statin can work side by side. The statin handles LDL. Weight loss on tirzepatide helps with triglycerides, HDL, blood pressure, and blood sugar. If you take both, keep taking your statin unless your prescriber changes it. The glp1.md site covers the wider GLP-1 drug class.

The bottom line

Mounjaro clearly lowers triglycerides, by roughly 20% to 29% in trials, and raises HDL by about 7% to 10%. Its effect on LDL is small, about 5% to 7% at best, and in people with diabetes LDL still rose slightly. The drug is FDA-approved to reduce cardiovascular events in high-risk type 2 diabetes, but it is not a substitute for statin therapy. Ask for a lipid panel before you start and a repeat after a few months at your maintenance dose.

Last updated: September 2026. This article is for informational purposes only and does not constitute medical advice. Talk with your prescriber before you start, stop, or change any cholesterol or diabetes medication.